Posts By :

Anna Stelling, PhD

Anna Stelling, PhD

The risk of a clinical event in radiologically isolated syndrome

2560 1707 Anna Stelling, PhD

Radiologically isolated syndrome (RIS) is a clinical finding that describes individuals with magnetic resonance imaging (MRI) patterns similar to those seen in multiple sclerosis patients. However, affected patients do not…

read more

Deep brain stimulation against chronic cluster headaches: Yes or no?

2560 1920 Anna Stelling, PhD

Cluster headaches, a disease belonging to the class of trigeminal autonomic cephalgias, are seen chronically in about 15% of all cluster headache patients.1,2 Affected individuals have always been treated with…

read more

Speaking to Prof. Andrea Rossetti – “Often in life, things happen by chance, but then you have to seize the chance“

2560 1600 Anna Stelling, PhD

Prof. Andrea Rossetti is the head of the Electroencephalography (EEG) and Epilepsy unit of the Neurological department of the University Hospital of Lausanne in Switzerland. He recently published a potentially…

read more

New data on endovascular treatment in patients with cerebral venous thrombosis

2560 1707 Anna Stelling, PhD

Stroke can have several causes, and one of them is cerebral venous thrombosis (CVT), affecting mostly young adult and middle-aged patients.1 The current standard for CVT is anticoagulation treatment with…

read more

Deep brain stimulation in Parkinson’s disease – five-year outcomes

2560 1707 Anna Stelling, PhD

It has been consistently shown that deep brain stimulation (DBS) in combination with medication is superior to medication alone in mid- and advanced-stage Parkinson’s disease (PD).1 These findings also motivated…

read more

Ageing in multiple sclerosis – what do we know?

2846 1601 Anna Stelling, PhD

“Ageing comes with many issues in multiple sclerosis (MS): progression, comorbidities, cognition problems and response to treatment”, Pierre Duquette (Department of Neuroscience, University of Montreal, Canada), the chair of the…

read more

Is disease-modifying treatment in primary progressive multiple sclerosis effective after all?

1703 2560 Anna Stelling, PhD

Until now, several randomised controlled trials and real-world studies could not show the clinical benefit of disease‑modifying treatments (DMTs) in primary progressive multiple sclerosis (PPMS).1-4 However, some recently published results…

read more

Neurofilament light chain levels as a biomarker in multiple sclerosis

1703 2560 Anna Stelling, PhD

It has been previously shown that the neuronal cytoskeletal protein neurofilament light chain (NfL) is released into the blood and cerebrospinal fluid (CSF) upon neuroaxonal injury.1 Hence it was not…

read more

A reliable blood test for Alzheimer’s disease – is it becoming a reality?

1024 683 Anna Stelling, PhD

The increasing number of patients suffering from dementia caused by Alzheimer’s disease (AD) is a significant challenge for society and requires action by healthcare professionals and researchers worldwide. One important…

read more

Speaking to Prof. Günther Deuschl – “The world is not a world of competitors, it is a world of collaborators.“

1041 1092 Anna Stelling, PhD

Even now, after having retired, Prof. Günther Deuschl’s ultimate goal is to cure patients. As an expert in movement disorders, he has contributed to this field substantially during his career.…

read more
Brainwork is supported by unrestricted grants from: